The utilization of AlloSure to help guide immunosuppression management in solid organ transplant recipients diagnosed with COVID-19
An observational case series of patients with solid organ transplants who have been admitted
with suspected COVID-19 utilizing AlloSure dd-cf DNA to help guide immunosuppression
management balancing the treatment of sepsis and avoiding allograft rejection.
- Liver, Heart, Lung or Kidney organ transplant recipient with a suspected or confirmed
diagnosis of COVID-19